2.65
-0.14(-5.02%)
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
300
First IPO Date
November 05, 2021
| Name | Title | Pay | Year Born |
| Joshua G. Liang | Chief Executive Officer & Executive Director | 4.71M | 1993 |
| Peng Liang | Founder, Chief Scientific Officer & Chairman of the Board | 4.84M | 1961 |
| Berry Michael | Chief Technical Operation Officer | 0 | 1966 |
| Igor Smolenov | Executive Vice President of Global Clinical Development Vaccines | 0 | N/A |
| Nicholas Jackson | President of Global R&D and Alliances | 0 | 1971 |
| Yang Li | Chief Technology Officer | 0 | N/A |
| LiongHo Chua | President of Greater China | 0 | 1964 |
| Nicolas Burdin | Global Head of R&D | 0 | N/A |
| Htay Htay Han | Chief Medical Officer of Vaccine | 0 | 1969 |
| Tracy Wang | Senior Vice President of Head of Regulatory Affairs, China | 0 | N/A |
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.